Sign In
Buy GWPH
$218.96
+0 (+0%)
At Close: May 27, 2022
GW Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference
07:30am, Monday, 09'th Nov 2020
LONDON and CARLSBAD, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of
9 Cannabis Stocks Making Moves During an Explosive U.S. Election Week
08:53am, Friday, 06'th Nov 2020
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks last week and we will look ahead at the pot stocks to watch
Goldman Sachs Shifts Price Targets on 4 Red-Hot Stocks to Buy
08:24am, Friday, 06'th Nov 2020
With the fourth quarter almost half over, and most of the third-quarter earnings reports long since posted, most on Wall Street are reasonably satisfied with the results.
GW Pharmaceuticals Plc Remains A Solid Growth Story
07:30pm, Thursday, 05'th Nov 2020
GW Pharmaceuticals' latest earnings report reinforces the narrative that the company's future growth trajectory looks solid. Epidiolex still has a lot of growth potential in the short and long term, w
Election 2020: What cannabis legalization means for investors and the cannabis sector
02:58pm, Wednesday, 04'th Nov 2020
Vivien Azer Cowen Managing Director and Senior Research Analyst discusses the election day and the impact of cannabis legalization on stocks. #cannabis #marijuana #cannabislegalization Subscribe to Ya
Cannabis Biotech Continues Two-Day Run On Unexpected Sales Beat
11:28am, Wednesday, 04'th Nov 2020
GW Pharmaceuticals is an "underappreciated story," an analyst said as GWPH stock jumped higher on Wednesday for the second day running on better-than-expected third-quarter revenue. The post Cannabis
GW Pharmaceuticals News: Why GWPH Stock Is Running 27% High Today
10:22am, Wednesday, 04'th Nov 2020
GW Pharmaceuticals (GWPH) news for Wednesday includes GWPH stock continuing to rise after the release of its Q3 earnings report yesterday. The post GW Pharmaceuticals News: Why GWPH Stock Is Running 2
GW Pharmaceuticals plc's (GWPH) CEO Justin Gover on Q3 2020 Results - Earnings Call Transcript
02:05pm, Tuesday, 03'rd Nov 2020
GW Pharmaceuticals plc's (GWPH) CEO Justin Gover on Q3 2020 Results - Earnings Call Transcript
Cannabis Watch: GW Pharma shares rally on earnings and news of late-stage trial of cannabis-based treatment for MS patients
01:58pm, Tuesday, 03'rd Nov 2020
Shares of GW Pharmaceuticals PLC jumped 18% Tuesday, after the biotech posted a narrower-than-expected third-quarter loss and a revenue beat and said a delayed late-stage trial of its cannabinoid-base
GW Pharmaceuticals Initiates Phase 3 Trial for Multiple Sclerosis Drug
01:01pm, Tuesday, 03'rd Nov 2020
The cannabinoid prescription drug Sativex has already been approved in numerous countries for reducing spasticity caused by MS.
GW Pharmaceuticals loss narrows more than expected and revenue beats; stock rallies
07:47am, Tuesday, 03'rd Nov 2020
Shares of GW Pharmaceuticals PLC rallied 4.7% in premarket trading Tuesday, after the biopharmaceutical company developing therapeutics from its cannabinoid product platform reported a narrower-than-e
GW Pharmaceuticals stock set to rally after Phase 3 trial of MS treatment to start, after COVID-19-related delay
07:30am, Tuesday, 03'rd Nov 2020
Shares of GW Pharmaceuticals PLC were indicated up more than 6% in premarket trading Tuesday, after the biopharmaceutical company developing therapeutics from its cannabinoid product platform said it
GW Pharmaceuticals Initiates Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity
07:15am, Tuesday, 03'rd Nov 2020
CARLSBAD, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoi
GW Pharmaceuticals Q3 Earnings May Provide Clarity On Many Issues
06:00pm, Wednesday, 28'th Oct 2020
Investors should study the various revenue streams for "epidiolex". Level of cash reserves important to judge likelihood of future share dilution.
Zogenix: A Rich Bet On Poor Investor Sentiment And Exaggerated Commercialization Concerns (NASDAQ:ZGNX)
05:24pm, Thursday, 22'nd Oct 2020
Shares of Zogenix have been under pressure lately due to safety concerns surrounding its unique anti-epileptic drug, Fintepla.
